← Leaderboards
Charles C. McOsker
Clarametyx Bioscience, Inc.
$3,145,522
Attributed
$3,145,522
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2022–24$2M$1.5M$1M$500K$0
'22
'23
'24
Funding mix
By agency
NIH$3,145,522 · 1
By mechanism
R44$3,145,522 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Adjuvant”
- Warwick Britton · University Of Sydney$10,964,476
- Philip Felgner · University Of California-Irvine$10,234,165
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Li Liang · University Of California-Irvine$7,511,446
- Bruxanne El-Kammash · University Of Chicago$7,281,050
- Nicolas Collins · Vaccine Formulation Institute (Ch) Ltd$6,937,118
Research focus
AdjuvantAcuteAnalytical MethodAntibioticsAdvanced DevelopmentAntigensAssay DevelopmentBacteriaBacterial InfectionsBacterial VaccinesBacteriologyAntibodiesBehaviorBiological ProductsBiological SciencesCessation Of LifeCharacteristicsChildChildhoodChinchilla (Genus)ChronicClinical TrialsCo-InfectionCommercialization
Grant awards (3)
Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media$1,175,029
R44 · FY2024 · DC · contact PI
Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media$762,572
R44 · FY2023 · DC · contact PI
Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media$1,207,921
R44 · FY2022 · DC · contact PI